Literature DB >> 35621881

Fueling the fire in the gut.

Chia-Hao Lin1, Li-Fan Lu1,2,3.   

Abstract

Gut dysbiosis has long been associated with the development of Crohn's disease and other gastrointestinal disorders. Otake-Kasamoto et al. (2022. J. Exp. Med.https://doi.org/10.1084/jem.20211291) report that dysbiotic microbiota-derived bioactive lipids, lysophosphatidylserines, can promote pathological Th1 cell responses through inducing metabolic reprogramming and epigenetic changes.
© 2022 Lin and Lu.

Entities:  

Mesh:

Year:  2022        PMID: 35621881      PMCID: PMC9157397          DOI: 10.1084/jem.20220723

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   17.579


  13 in total

1.  Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease.

Authors:  Jochen Maul; Christoph Loddenkemper; Pamela Mundt; Erika Berg; Thomas Giese; Andreas Stallmach; Martin Zeitz; Rainer Duchmann
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

Review 2.  A review of the therapeutic management of Crohn's disease.

Authors:  Aditi Kumar; Alexander Cole; Jonathan Segal; Philip Smith; Jimmy K Limdi
Journal:  Therap Adv Gastroenterol       Date:  2022-02-17       Impact factor: 4.409

3.  Lysophosphatidylserines derived from microbiota in Crohn's disease elicit pathological Th1 response.

Authors:  Yuriko Otake-Kasamoto; Hisako Kayama; Hideki Iijima; Kiyoshi Takeda; Toshihiro Kishikawa; Shinichiro Shinzaki; Taku Tashiro; Takahiro Amano; Mizuki Tani; Takeo Yoshihara; Bo Li; Haruka Tani; Li Liu; Akio Hayashi; Daisuke Okuzaki; Daisuke Motooka; Shota Nakamura; Yukinori Okada; Tetsuo Takehara
Journal:  J Exp Med       Date:  2022-05-24       Impact factor: 17.579

4.  TGFα shedding assay: an accurate and versatile method for detecting GPCR activation.

Authors:  Asuka Inoue; Jun Ishiguro; Hajime Kitamura; Naoaki Arima; Michiyo Okutani; Akira Shuto; Shigeki Higashiyama; Tomohiko Ohwada; Hiroyuki Arai; Kumiko Makide; Junken Aoki
Journal:  Nat Methods       Date:  2012-09-16       Impact factor: 28.547

5.  Role of a serum phospholipase A1 in the phosphatidylserine-induced T cell inhibition.

Authors:  F Bellini; A Bruni
Journal:  FEBS Lett       Date:  1993-01-18       Impact factor: 4.124

6.  The lysophosphatidylserine receptor GPR174 constrains regulatory T cell development and function.

Authors:  Michael J Barnes; Chien-Ming Li; Ying Xu; Jinping An; Yong Huang; Jason G Cyster
Journal:  J Exp Med       Date:  2015-06-15       Impact factor: 14.307

7.  Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders.

Authors:  Hani Sbahi; Jack A Di Palma
Journal:  BMJ Open Gastroenterol       Date:  2016-05-09

8.  A microbial signature for Crohn's disease.

Authors:  Victoria Pascal; Marta Pozuelo; Natalia Borruel; Francesc Casellas; David Campos; Alba Santiago; Xavier Martinez; Encarna Varela; Guillaume Sarrabayrouse; Kathleen Machiels; Severine Vermeire; Harry Sokol; Francisco Guarner; Chaysavanh Manichanh
Journal:  Gut       Date:  2017-02-07       Impact factor: 23.059

9.  Lysophosphatidylserine suppression of T-cell activation via GPR174 requires Gαs proteins.

Authors:  Michael J Barnes; Jason G Cyster
Journal:  Immunol Cell Biol       Date:  2018-03-25       Impact factor: 5.126

Review 10.  Current Knowledge on the Biology of Lysophosphatidylserine as an Emerging Bioactive Lipid.

Authors:  Jumpei Omi; Kuniyuki Kano; Junken Aoki
Journal:  Cell Biochem Biophys       Date:  2021-06-15       Impact factor: 2.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.